Drug
Ipatasertib clinical trials
Also written GDC-0068 and RG7440.
- studies test it
- 48
- open now
- 7
- in phase 3
- 5
- first study started
- 2010
Keep track of what changes. Save the ipatasertib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
48 studies that test it; most in 2021 (10)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2017 | 6 |
| 2018 | 6 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 10 |
| 2022 | 3 |
| 2023 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 21
- Phase 2
- 31
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 26 · Other 22
Hoffmann-La Roche (16) · Genentech, Inc. (10) · National Cancer Institute (NCI) (7) · Queen Mary University of London (2) · Canadian Cancer Trials Group (2) · German Cancer Research Center (2) · Royal Marsden NHS Foundation Trust (1) · Institute of Cancer Research, United Kingdom (1)
Often tested with
Tested in the same studies.
Atezolizumab (17) · Bevacizumab (8) · Inavolisib (8) · Paclitaxel (7) · Cobimetinib (7) · Palbociclib (6) · Ado-Trastuzumab Emtansine (6) · Pertuzumab (5)
Studies
Open first, then newest update. How each study uses ipatasertib is read from its arms, and is right about nine times in ten.
Testing it · 48
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Ipatasertib
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Ipatasertib
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Written as Ipatasertib
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingPhase 3Hoffmann-La RocheNCT05862285Written as Ipatasertib
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingPhase 1/2Alliance Foundation Trials, LLC.NCT04486352Written as Ipatasertib
- Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)RecruitingPhase 2German Cancer Research CenterNCT05332561Written as Ipatasertib
- Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line ImmunotherapyRecruitingPhase 2Jun Zhang, MD, PhDNCT04467801Written as Ipatasertib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Ipatasertib
- Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial CancersActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT05538897Written as Ipatasertib
- Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT05276973Written as Ipatasertib
- Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05172258Written as Ipatasertib
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingPhase 2Hoffmann-La RocheNCT04931342Written as Ipatasertib
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845Written as Ipatasertib
- Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment TrialActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05554380Written as Ipatasertib
- Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)CompletedPhase 2Hospices Civils de LyonNCT04739202Written as Atezolizumab + Ipatasertib
- Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06400251Written as Ipatasertib
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedPhase 1/2Hoffmann-La RocheNCT03337698Written as Ipatasertib
- Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBCActive, not recruitingPhase 2Queen Mary University of LondonNCT05498896Written as Ipatasertib
- Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA SuppressionActive, not recruitingPhase 2Royal Marsden NHS Foundation TrustNCT04920708Written as Ipatasertib 300mg
- Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase InhibitorActive, not recruitingPhase 3Canadian Cancer Trials GroupNCT04650581Written as Ipatasertib
See all 48 studies that test ipatasertib →
Given in every arm · 6 — ipatasertib is usual care beside what is tested
- Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck CancerRecruitingPhase 1National Cancer Institute (NCI)NCT05172245Written as Ipatasertib
- AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)Active, not recruitingPhase 1Massachusetts General HospitalNCT03959891Written as Ipatasertib
- A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerCompletedPhase 1Hoffmann-La RocheNCT03800836Written as Ipatasertib
- Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast CancerCompletedPhase 2MedSIRNCT04464174Written as Ipatasertib
- Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast CancerCompletedPhase 1/2City of Hope Medical CenterNCT03853707Written as Ipatasertib
- Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid TumorsCompletedPhase 1Genentech, Inc.NCT01362374Written as Ipatasertib
Codes
What other systems call ipatasertib · ClinicalTrials.gg INT006352
- MeSH (NLM) C583616ipatasertibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 524Y3IB4HQIPATASERTIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27078088ipatasertibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91072IpatasertibOne source FDA
- DrugBank DB11743One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C583616 | ipatasertib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 524Y3IB4HQ | IPATASERTIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27078088 | ipatasertib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91072 | Ipatasertib | One source FDA |
| DrugBank | DB11743 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.